Geode Capital Management LLC Makes New Investment in Septerna, Inc. (NASDAQ:SEPN)

Geode Capital Management LLC acquired a new stake in Septerna, Inc. (NASDAQ:SEPN - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 380,577 shares of the company's stock, valued at approximately $8,717,000. Geode Capital Management LLC owned 0.86% of Septerna as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. JPMorgan Chase & Co. acquired a new position in shares of Septerna in the fourth quarter worth about $871,000. Corebridge Financial Inc. purchased a new position in Septerna during the fourth quarter worth approximately $212,000. Vanguard Group Inc. acquired a new stake in Septerna in the fourth quarter valued at approximately $22,557,000. PNC Financial Services Group Inc. acquired a new stake in Septerna in the fourth quarter valued at approximately $61,000. Finally, Lindbrook Capital LLC acquired a new position in shares of Septerna during the 4th quarter worth approximately $481,000.

Insider Activity at Septerna

In other news, Director Alan Ezekowitz acquired 7,491 shares of the business's stock in a transaction that occurred on Tuesday, March 4th. The stock was purchased at an average cost of $6.35 per share, for a total transaction of $47,567.85. Following the completion of the transaction, the director now owns 24,911 shares in the company, valued at approximately $158,184.85. This trade represents a 43.00 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Gil M. Labrucherie bought 5,000 shares of Septerna stock in a transaction on Friday, February 21st. The shares were purchased at an average cost of $5.85 per share, for a total transaction of $29,250.00. Following the completion of the purchase, the chief financial officer now directly owns 30,000 shares of the company's stock, valued at $175,500. This trade represents a 20.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last 90 days, insiders purchased 74,346 shares of company stock valued at $439,670.

Wall Street Analysts Forecast Growth

SEPN has been the topic of a number of research analyst reports. Cantor Fitzgerald reissued an "overweight" rating and issued a $50.00 price target on shares of Septerna in a research note on Tuesday, February 11th. Wells Fargo & Company cut their target price on shares of Septerna from $14.00 to $11.00 and set an "equal weight" rating for the company in a research note on Friday, March 28th.

Septerna Price Performance

SEPN stock remained flat at $6.46 during midday trading on Friday. The company's stock had a trading volume of 173,738 shares, compared to its average volume of 428,560. Septerna, Inc. has a 12 month low of $4.17 and a 12 month high of $28.99. The firm's 50-day moving average is $5.95.

Septerna (NASDAQ:SEPN - Get Free Report) last posted its quarterly earnings results on Thursday, March 27th. The company reported ($0.64) earnings per share for the quarter, topping the consensus estimate of ($0.69) by $0.05. The business had revenue of $0.21 million during the quarter, compared to analysts' expectations of $0.13 million. As a group, equities research analysts predict that Septerna, Inc. will post -7.11 earnings per share for the current year.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.